Literature DB >> 21911339

Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events.

Lasse Jespersen1, Anders Hvelplund, Steen Z Abildstrøm, Frants Pedersen, Søren Galatius, Jan K Madsen, Erik Jørgensen, Henning Kelbæk, Eva Prescott.   

Abstract

AIMS: Patients with chest pain and no obstructive coronary artery disease (CAD) are considered at low risk for cardiovascular events but evidence supporting this is scarce. We investigated the prognostic implications of stable angina pectoris in relation to the presence and degree of CAD with no obstructive CAD in focus. METHODS AND
RESULTS: We identified 11 223 patients referred for coronary angiography (CAG) in 1998-2009 with stable angina pectoris as indication and 5705 participants from the Copenhagen City Heart Study for comparison. Main outcome measures were major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, stroke or heart failure, and all-cause mortality. Significantly more women (65%) than men (32%) had no obstructive CAD (P< 0.001). In Cox's models adjusted for age, body mass index, diabetes, smoking, and use of lipid-lowering or antihypertensive medication, hazard ratios (HRs) associated with no obstructive CAD were similar in men and women. In the pooled analysis, the risk of MACE increased with increasing degrees of CAD with multivariable-adjusted HRs of 1.52 (95% confidence interval, 1.27-1.83) for patients with normal coronary arteries and 1.85 (1.51-2.28) for patients with diffuse non-obstructive CAD compared with the reference population. For all-cause mortality, normal coronary arteries and diffuse non-obstructive CAD were associated with HRs of 1.29 (1.07-1.56) and 1.52 (1.24-1.88), respectively.
CONCLUSION: Patients with stable angina and normal coronary arteries or diffuse non-obstructive CAD have elevated risks of MACE and all-cause mortality compared with a reference population without ischaemic heart disease.

Entities:  

Mesh:

Year:  2011        PMID: 21911339     DOI: 10.1093/eurheartj/ehr331

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  212 in total

1.  Nonobstructive coronary artery disease and risk of myocardial infarction.

Authors:  Thomas M Maddox; Maggie A Stanislawski; Gary K Grunwald; Steven M Bradley; P Michael Ho; Thomas T Tsai; Manesh R Patel; Amneet Sandhu; Javier Valle; David J Magid; Benjamin Leon; Deepak L Bhatt; Stephan D Fihn; John S Rumsfeld
Journal:  JAMA       Date:  2014-11-05       Impact factor: 56.272

2.  Safety of coronary reactivity testing in women with no obstructive coronary artery disease: results from the NHLBI-sponsored WISE (Women's Ischemia Syndrome Evaluation) study.

Authors:  Janet Wei; Puja K Mehta; B Delia Johnson; Bruce Samuels; Saibal Kar; R David Anderson; Babak Azarbal; John Petersen; Barry Sharaf; Eileen Handberg; Chrisandra Shufelt; Kamlesh Kothawade; George Sopko; Amir Lerman; Leslee Shaw; Sheryl F Kelsey; Carl J Pepine; C Noel Bairey Merz
Journal:  JACC Cardiovasc Interv       Date:  2012-06       Impact factor: 11.195

Review 3.  Emergence of Nonobstructive Coronary Artery Disease: A Woman's Problem and Need for Change in Definition on Angiography.

Authors:  Carl J Pepine; Keith C Ferdinand; Leslee J Shaw; Kelly Ann Light-McGroary; Rashmee U Shah; Martha Gulati; Claire Duvernoy; Mary Norine Walsh; C Noel Bairey Merz
Journal:  J Am Coll Cardiol       Date:  2015-10-27       Impact factor: 24.094

4.  Prognostic significance of calcified plaque among symptomatic patients with nonobstructive coronary artery disease.

Authors:  Sana Shah; Naveen Bellam; Jonathon Leipsic; Daniel S Berman; Arshed Quyyumi; Jörg Hausleiter; Stephan Achenbach; Mouaz Al-Mallah; Matthew J Budoff; Fillippo Cademartiri; Tracy Q Callister; Hyuk-Jae Chang; Benjamin J W Chow; Ricardo C Cury; Augustin J Delago; Allison L Dunning; Gudrun M Feuchtner; Martin Hadamitzky; Ronald P Karlsberg; Philipp A Kaufmann; Fay Y Lin; Kavitha M Chinnaiyan; Erica Maffei; Gilbert L Raff; Todd C Villines; Millie J Gomez; James K Min; Leslee J Shaw
Journal:  J Nucl Cardiol       Date:  2014-03-29       Impact factor: 5.952

5.  Ischemic Predictors of Outcomes in Women With Signs and Symptoms of Ischemia and Nonobstructive Coronary Artery Disease.

Authors:  Tara L Sedlak; Meijiao Guan; May Lee; Karin H Humphries; B Delia Johnson; Carl J Pepine; C Noel Bairey Merz
Journal:  JAMA Cardiol       Date:  2016-07-01       Impact factor: 14.676

6.  Gender-Related Differences in Clinical Presentation and Angiographic Findings in Patients with Ischemia and No Obstructive Coronary Artery Disease (INOCA): A Single-Center Observational Registry.

Authors:  Mauro Gitto; Francesco Gentile; Alexandra N Nowbar; Alaide Chieffo; Rasha Al-Lamee
Journal:  Int J Angiol       Date:  2020-05-14

7.  Feasibility of dynamic stress 201Tl/rest 99mTc-tetrofosmin single photon emission computed tomography for quantification of myocardial perfusion reserve in patients with stable coronary artery disease.

Authors:  Sangwon Han; Young-Hak Kim; Jung-Min Ahn; Soo-Jin Kang; Jungsu S Oh; Eonwoo Shin; Changhwan Sung; Sun Young Chae; Seung-Jung Park; Gillan Grimberg; Gil Kovalski; Dae Hyuk Moon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-02       Impact factor: 9.236

Review 8.  Sex-specific factors in microvascular angina.

Authors:  Tara Sedlak; Mona Izadnegahdar; Karin H Humphries; C Noel Bairey Merz
Journal:  Can J Cardiol       Date:  2014-02-27       Impact factor: 5.223

Review 9.  Cardiac Syndrome X: update 2014.

Authors:  Shilpa Agrawal; Puja K Mehta; C Noel Bairey Merz
Journal:  Cardiol Clin       Date:  2014-06-02       Impact factor: 2.213

10.  Increased wave reflection and ejection duration in women with chest pain and nonobstructive coronary artery disease: ancillary study from the Women's Ischemia Syndrome Evaluation.

Authors:  Wilmer W Nichols; Scott J Denardo; B Delia Johnson; Barry L Sharaf; C Noel Bairey Merz; Carl J Pepine
Journal:  J Hypertens       Date:  2013-07       Impact factor: 4.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.